1 Market Overview

1.1 Product Overview and Scope of Benign Prostatic Hyperplasia Treatment

1.2 Classification of Benign Prostatic Hyperplasia Treatment by Type

1.2.1 Overview: Global Benign Prostatic Hyperplasia Treatment Market Size by Type: 2020 Versus 2021 Versus 2026

1.2.2 Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Type in 2020

1.2.3 Drug Class

1.2.4 Minimally Invasive Surgeries

1.2.5 Laser Therapy

1.2.6 Others

1.3 Global Benign Prostatic Hyperplasia Treatment Market by Application

1.3.1 Overview: Global Benign Prostatic Hyperplasia Treatment Market Size by Application: 2020 Versus 2021 Versus 2026

1.3.2 Hospitals

1.3.3 Ambulatory Surgical Centers

1.3.4 Specialty Clinics

1.3.5 Others

1.4 Global Benign Prostatic Hyperplasia Treatment Market Size & Forecast

1.5 Global Benign Prostatic Hyperplasia Treatment Market Size and Forecast by Region

1.5.1 Global Benign Prostatic Hyperplasia Treatment Market Size by Region: 2016 VS 2021 VS 2026

1.5.2 Global Benign Prostatic Hyperplasia Treatment Market Size by Region, (2016-2021)

1.5.3 North America Benign Prostatic Hyperplasia Treatment Market Size and Prospect (2016-2026)

1.5.4 Europe Benign Prostatic Hyperplasia Treatment Market Size and Prospect (2016-2026)

1.5.5 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size and Prospect (2016-2026)

1.5.6 South America Benign Prostatic Hyperplasia Treatment Market Size and Prospect (2016-2026)

1.5.7 Middle East and Africa Benign Prostatic Hyperplasia Treatment Market Size and Prospect (2016-2026)

1.6 Market Drivers, Restraints and Trends

1.6.1 Benign Prostatic Hyperplasia Treatment Market Drivers

1.6.2 Benign Prostatic Hyperplasia Treatment Market Restraints

1.6.3 Benign Prostatic Hyperplasia Treatment Trends Analysis

2 Company Profiles

2.1 Abbott

2.1.1 Abbott Details

2.1.2 Abbott Major Business

2.1.3 Abbott Benign Prostatic Hyperplasia Treatment Product and Solutions

2.1.4 Abbott Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.1.5 Abbott Recent Developments and Future Plans

2.2 Allergan plc

2.2.1 Allergan plc Details

2.2.2 Allergan plc Major Business

2.2.3 Allergan plc Benign Prostatic Hyperplasia Treatment Product and Solutions

2.2.4 Allergan plc Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.2.5 Allergan plc Recent Developments and Future Plans

2.3 Astellas Pharma

2.3.1 Astellas Pharma Details

2.3.2 Astellas Pharma Major Business

2.3.3 Astellas Pharma Benign Prostatic Hyperplasia Treatment Product and Solutions

2.3.4 Astellas Pharma Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.3.5 Astellas Pharma Recent Developments and Future Plans

2.4 Asahi Kasei Corporation

2.4.1 Asahi Kasei Corporation Details

2.4.2 Asahi Kasei Corporation Major Business

2.4.3 Asahi Kasei Corporation Benign Prostatic Hyperplasia Treatment Product and Solutions

2.4.4 Asahi Kasei Corporation Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.4.5 Asahi Kasei Corporation Recent Developments and Future Plans

2.5 Boehringer Ingelheim GmbH

2.5.1 Boehringer Ingelheim GmbH Details

2.5.2 Boehringer Ingelheim GmbH Major Business

2.5.3 Boehringer Ingelheim GmbH Benign Prostatic Hyperplasia Treatment Product and Solutions

2.5.4 Boehringer Ingelheim GmbH Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.5.5 Boehringer Ingelheim GmbH Recent Developments and Future Plans

2.6 GlaxoSmithKline

2.6.1 GlaxoSmithKline Details

2.6.2 GlaxoSmithKline Major Business

2.6.3 GlaxoSmithKline Benign Prostatic Hyperplasia Treatment Product and Solutions

2.6.4 GlaxoSmithKline Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.6.5 GlaxoSmithKline Recent Developments and Future Plans

2.7 Pfizer

2.7.1 Pfizer Details

2.7.2 Pfizer Major Business

2.7.3 Pfizer Benign Prostatic Hyperplasia Treatment Product and Solutions

2.7.4 Pfizer Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.7.5 Pfizer Recent Developments and Future Plans

2.8 Sanofi

2.8.1 Sanofi Details

2.8.2 Sanofi Major Business

2.8.3 Sanofi Benign Prostatic Hyperplasia Treatment Product and Solutions

2.8.4 Sanofi Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.8.5 Sanofi Recent Developments and Future Plans

2.9 Teva Pharmaceutical Industries

2.9.1 Teva Pharmaceutical Industries Details

2.9.2 Teva Pharmaceutical Industries Major Business

2.9.3 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia Treatment Product and Solutions

2.9.4 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.9.5 Teva Pharmaceutical Industries Recent Developments and Future Plans

2.10 Merck

2.10.1 Merck Details

2.10.2 Merck Major Business

2.10.3 Merck Benign Prostatic Hyperplasia Treatment Product and Solutions

2.10.4 Merck Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.10.5 Merck Recent Developments and Future Plans

2.11 Boston Scientific Corporation

2.11.1 Boston Scientific Corporation Details

2.11.2 Boston Scientific Corporation Major Business

2.11.3 Boston Scientific Corporation Benign Prostatic Hyperplasia Treatment Product and Solutions

2.11.4 Boston Scientific Corporation Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.11.5 Boston Scientific Corporation Recent Developments and Future Plans

2.12 Teleflex Incorporated

2.12.1 Teleflex Incorporated Details

2.12.2 Teleflex Incorporated Major Business

2.12.3 Teleflex Incorporated Benign Prostatic Hyperplasia Treatment Product and Solutions

2.12.4 Teleflex Incorporated Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.12.5 Teleflex Incorporated Recent Developments and Future Plans

2.13 Endo International

2.13.1 Endo International Details

2.13.2 Endo International Major Business

2.13.3 Endo International Benign Prostatic Hyperplasia Treatment Product and Solutions

2.13.4 Endo International Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.13.5 Endo International Recent Developments and Future Plans

2.14 Urologix

2.14.1 Urologix Details

2.14.2 Urologix Major Business

2.14.3 Urologix Benign Prostatic Hyperplasia Treatment Product and Solutions

2.14.4 Urologix Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.14.5 Urologix Recent Developments and Future Plans

2.15 LISA Laser

2.15.1 LISA Laser Details

2.15.2 LISA Laser Major Business

2.15.3 LISA Laser Benign Prostatic Hyperplasia Treatment Product and Solutions

2.15.4 LISA Laser Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.15.5 LISA Laser Recent Developments and Future Plans

2.16 Olympus

2.16.1 Olympus Details

2.16.2 Olympus Major Business

2.16.3 Olympus Benign Prostatic Hyperplasia Treatment Product and Solutions

2.16.4 Olympus Benign Prostatic Hyperplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)

2.16.5 Olympus Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Benign Prostatic Hyperplasia Treatment Revenue and Share by Players (2019-2021)

3.2 Market Concentration Rate

3.2.1 Top 3 Benign Prostatic Hyperplasia Treatment Players Market Share

3.2.2 Top 10 Benign Prostatic Hyperplasia Treatment Players Market Share

3.2.3 Market Competition Trend

3.3 Benign Prostatic Hyperplasia Treatment Players Head Office, Products and Services Provided

3.4 Mergers & Acquisitions

3.5 New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Benign Prostatic Hyperplasia Treatment Revenue and Market Share by Type (2016-2021)

4.2 Global Benign Prostatic Hyperplasia Treatment Market Forecast by Type (2021-2026)

5 Market Size Segment by Application

5.1 Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Application (2016-2021)

5.2 Benign Prostatic Hyperplasia Treatment Market Forecast by Application (2021-2026)

6 North America by Country, by Type, and by Application

6.1 North America Benign Prostatic Hyperplasia Treatment Revenue by Type (2016-2026)

6.2 North America Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2026)

6.3 North America Benign Prostatic Hyperplasia Treatment Market Size by Country

6.3.1 North America Benign Prostatic Hyperplasia Treatment Revenue by Country (2016-2026)

6.3.2 United States Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)

6.3.3 Canada Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)

6.3.4 Mexico Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)

7 Europe by Country, by Type, and by Application

7.1 Europe Benign Prostatic Hyperplasia Treatment Revenue by Type (2016-2026)

7.2 Europe Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2026)

7.3 Europe Benign Prostatic Hyperplasia Treatment Market Size by Country

7.3.1 Europe Benign Prostatic Hyperplasia Treatment Revenue by Country (2016-2026)

7.3.2 Germany Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)

7.3.3 France Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)

7.3.4 United Kingdom Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)

7.3.5 Russia Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)

7.3.6 Italy Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Benign Prostatic Hyperplasia Treatment Revenue by Type (2016-2026)

8.2 Asia-Pacific Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2026)

8.3 Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Size by Region

8.3.1 Asia-Pacific Benign Prostatic Hyperplasia Treatment Revenue by Region (2016-2026)

8.3.2 China Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)

8.3.3 Japan Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)

8.3.4 South Korea Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)

8.3.5 India Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)

8.3.6 Southeast Asia Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)

8.3.7 Australia Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)

9 South America by Country, by Type, and by Application

9.1 South America Benign Prostatic Hyperplasia Treatment Revenue by Type (2016-2026)

9.2 South America Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2026)

9.3 South America Benign Prostatic Hyperplasia Treatment Market Size by Country

9.3.1 South America Benign Prostatic Hyperplasia Treatment Revenue by Country (2016-2026)

9.3.2 Brazil Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)

9.3.3 Argentina Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Benign Prostatic Hyperplasia Treatment Revenue by Type (2016-2026)

10.2 Middle East & Africa Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2026)

10.3 Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Size by Country

10.3.1 Middle East & Africa Benign Prostatic Hyperplasia Treatment Revenue by Country (2016-2026)

10.3.2 Turkey Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)

10.3.3 Saudi Arabia Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)

10.3.4 UAE Benign Prostatic Hyperplasia Treatment Market Size and Forecast (2016-2026)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Benign Prostatic Hyperplasia Treatment Revenue by Type, (USD Million), 2020 VS 2021 VS 2026

Table 2. Global Benign Prostatic Hyperplasia Treatment Revenue by Application, (USD Million), 2020 VS 2021 VS 2026

Table 3. Global Market Benign Prostatic Hyperplasia Treatment Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)

Table 4. Global Benign Prostatic Hyperplasia Treatment Revenue (USD Million) by Region (2016-2021)

Table 5. Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Region (2021-2026)

Table 6. Abbott Corporate Information, Head Office, and Major Competitors

Table 7. Abbott Major Business

Table 8. Abbott Benign Prostatic Hyperplasia Treatment Product and Solutions

Table 9. Abbott Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 10. Allergan plc Corporate Information, Head Office, and Major Competitors

Table 11. Allergan plc Major Business

Table 12. Allergan plc Benign Prostatic Hyperplasia Treatment Product and Solutions

Table 13. Allergan plc Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 14. Astellas Pharma Corporate Information, Head Office, and Major Competitors

Table 15. Astellas Pharma Major Business

Table 16. Astellas Pharma Benign Prostatic Hyperplasia Treatment Product and Solutions

Table 17. Astellas Pharma Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 18. Asahi Kasei Corporation Corporate Information, Head Office, and Major Competitors

Table 19. Asahi Kasei Corporation Major Business

Table 20. Asahi Kasei Corporation Benign Prostatic Hyperplasia Treatment Product and Solutions

Table 21. Asahi Kasei Corporation Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 22. Boehringer Ingelheim GmbH Corporate Information, Head Office, and Major Competitors

Table 23. Boehringer Ingelheim GmbH Major Business

Table 24. Boehringer Ingelheim GmbH Benign Prostatic Hyperplasia Treatment Product and Solutions

Table 25. Boehringer Ingelheim GmbH Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 26. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors

Table 27. GlaxoSmithKline Major Business

Table 28. GlaxoSmithKline Benign Prostatic Hyperplasia Treatment Product and Solutions

Table 29. GlaxoSmithKline Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 30. Pfizer Corporate Information, Head Office, and Major Competitors

Table 31. Pfizer Major Business

Table 32. Pfizer Benign Prostatic Hyperplasia Treatment Product and Solutions

Table 33. Pfizer Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 34. Sanofi Corporate Information, Head Office, and Major Competitors

Table 35. Sanofi Major Business

Table 36. Sanofi Benign Prostatic Hyperplasia Treatment Product and Solutions

Table 37. Sanofi Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 38. Teva Pharmaceutical Industries Corporate Information, Head Office, and Major Competitors

Table 39. Teva Pharmaceutical Industries Major Business

Table 40. Teva Pharmaceutical Industries Benign Prostatic Hyperplasia Treatment Product and Solutions

Table 41. Teva Pharmaceutical Industries Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 42. Merck Corporate Information, Head Office, and Major Competitors

Table 43. Merck Major Business

Table 44. Merck Benign Prostatic Hyperplasia Treatment Product and Solutions

Table 45. Merck Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 46. Boston Scientific Corporation Corporate Information, Head Office, and Major Competitors

Table 47. Boston Scientific Corporation Major Business

Table 48. Boston Scientific Corporation Benign Prostatic Hyperplasia Treatment Product and Solutions

Table 49. Boston Scientific Corporation Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 50. Teleflex Incorporated Corporate Information, Head Office, and Major Competitors

Table 51. Teleflex Incorporated Major Business

Table 52. Teleflex Incorporated Benign Prostatic Hyperplasia Treatment Product and Solutions

Table 53. Teleflex Incorporated Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 54. Endo International Corporate Information, Head Office, and Major Competitors

Table 55. Endo International Major Business

Table 56. Endo International Benign Prostatic Hyperplasia Treatment Product and Solutions

Table 57. Endo International Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 58. Urologix Corporate Information, Head Office, and Major Competitors

Table 59. Urologix Major Business

Table 60. Urologix Benign Prostatic Hyperplasia Treatment Product and Solutions

Table 61. Urologix Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 62. LISA Laser Corporate Information, Head Office, and Major Competitors

Table 63. LISA Laser Major Business

Table 64. LISA Laser Benign Prostatic Hyperplasia Treatment Product and Solutions

Table 65. LISA Laser Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 66. Olympus Corporate Information, Head Office, and Major Competitors

Table 67. Olympus Major Business

Table 68. Olympus Benign Prostatic Hyperplasia Treatment Product and Solutions

Table 69. Olympus Benign Prostatic Hyperplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)

Table 70. Global Benign Prostatic Hyperplasia Treatment Revenue (USD Million) by Players (2019-2021)

Table 71. Global Benign Prostatic Hyperplasia Treatment Revenue Share by Players (2019-2021)

Table 72. Breakdown of Benign Prostatic Hyperplasia Treatment by Company Type (Tier 1, Tier 2 and Tier 3)

Table 73. Benign Prostatic Hyperplasia Treatment Players Head Office, Products and Services Provided

Table 74. Benign Prostatic Hyperplasia Treatment Mergers & Acquisitions in the Past Five Years

Table 75. Benign Prostatic Hyperplasia Treatment New Entrants and Expansion Plans

Table 76. Global Benign Prostatic Hyperplasia Treatment Revenue (USD Million) by Type (2016-2021)

Table 77. Global Benign Prostatic Hyperplasia Treatment Revenue Share by Type (2016-2021)

Table 78. Global Benign Prostatic Hyperplasia Treatment Revenue Forecast by Type (2021-2026)

Table 79. Global Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2021)

Table 80. Global Benign Prostatic Hyperplasia Treatment Revenue Forecast by Application (2021-2026)

Table 81. North America Benign Prostatic Hyperplasia Treatment Revenue by Type (2016-2021) & (USD Million)

Table 82. North America Benign Prostatic Hyperplasia Treatment Revenue by Type (2021-2026) & (USD Million)

Table 83. North America Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2021) & (USD Million)

Table 84. North America Benign Prostatic Hyperplasia Treatment Revenue by Application (2021-2026) & (USD Million)

Table 85. North America Benign Prostatic Hyperplasia Treatment Revenue by Country (2016-2021) & (USD Million)

Table 86. North America Benign Prostatic Hyperplasia Treatment Revenue by Country (2021-2026) & (USD Million)

Table 87. Europe Benign Prostatic Hyperplasia Treatment Revenue by Type (2016-2021) & (USD Million)

Table 88. Europe Benign Prostatic Hyperplasia Treatment Revenue by Type (2021-2026) & (USD Million)

Table 89. Europe Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2021) & (USD Million)

Table 90. Europe Benign Prostatic Hyperplasia Treatment Revenue by Application (2021-2026) & (USD Million)

Table 91. Europe Benign Prostatic Hyperplasia Treatment Revenue by Country (2016-2021) & (USD Million)

Table 92. Europe Benign Prostatic Hyperplasia Treatment Revenue by Country (2021-2026) & (USD Million)

Table 93. Asia-Pacific Benign Prostatic Hyperplasia Treatment Revenue by Type (2016-2021) & (USD Million)

Table 94. Asia-Pacific Benign Prostatic Hyperplasia Treatment Revenue by Type (2021-2026) & (USD Million)

Table 95. Asia-Pacific Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2021) & (USD Million)

Table 96. Asia-Pacific Benign Prostatic Hyperplasia Treatment Revenue by Application (2021-2026) & (USD Million)

Table 97. Asia-Pacific Benign Prostatic Hyperplasia Treatment Revenue by Region (2016-2021) & (USD Million)

Table 98. Asia-Pacific Benign Prostatic Hyperplasia Treatment Revenue by Region (2021-2026) & (USD Million)

Table 99. South America Benign Prostatic Hyperplasia Treatment Revenue by Type (2016-2021) & (USD Million)

Table 100. South America Benign Prostatic Hyperplasia Treatment Revenue by Type (2021-2026) & (USD Million)

Table 101. South America Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2021) & (USD Million)

Table 102. South America Benign Prostatic Hyperplasia Treatment Revenue by Application (2021-2026) & (USD Million)

Table 103. South America Benign Prostatic Hyperplasia Treatment Revenue by Country (2016-2021) & (USD Million)

Table 104. South America Benign Prostatic Hyperplasia Treatment Revenue by Country (2021-2026) & (USD Million)

Table 105. Middle East & Africa Benign Prostatic Hyperplasia Treatment Revenue by Type (2016-2021) & (USD Million)

Table 106. Middle East & Africa Benign Prostatic Hyperplasia Treatment Revenue by Type (2021-2026) & (USD Million)

Table 107. Middle East & Africa Benign Prostatic Hyperplasia Treatment Revenue by Application (2016-2021) & (USD Million)

Table 108. Middle East & Africa Benign Prostatic Hyperplasia Treatment Revenue by Application (2021-2026) & (USD Million)

Table 109. Middle East & Africa Benign Prostatic Hyperplasia Treatment Revenue by Country (2016-2021) & (USD Million)

Table 110. Middle East & Africa Benign Prostatic Hyperplasia Treatment Revenue by Country (2021-2026) & (USD Million)

List of Figures

Figure 1. Benign Prostatic Hyperplasia Treatment Picture

Figure 2. Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Type in 2020

Figure 3. Drug Class

Figure 4. Minimally Invasive Surgeries

Figure 5. Laser Therapy

Figure 6. Others

Figure 7. Benign Prostatic Hyperplasia Treatment Revenue Market Share by Application in 2020

Figure 8. Hospitals Picture

Figure 9. Ambulatory Surgical Centers Picture

Figure 10. Specialty Clinics Picture

Figure 11. Others Picture

Figure 12. Global Benign Prostatic Hyperplasia Treatment Revenue, (USD Million): 2020 VS 2021 VS 2026

Figure 13. Global Benign Prostatic Hyperplasia Treatment Revenue and Forecast (2016-2026) & (USD Million)

Figure 14. Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Region (2016-2026)

Figure 15. Global Benign Prostatic Hyperplasia Treatment Revenue Market Share by Region in 2020

Figure 16. North America Benign Prostatic Hyperplasia Treatment Revenue (USD Million) and Growth Rate (2016-2026)

Figure 17. Europe Benign Prostatic Hyperplasia Treatment Revenue (USD Million) and Growth Rate (2016-2026)

Figure 18. Asia-Pacific Benign Prostatic Hyperplasia Treatment Revenue (USD Million) and Growth Rate (2016-2026)

Figure 19. South America Benign Prostatic Hyperplasia Treatment Revenue (USD Million) and Growth Rate (2016-2026)

Figure 20. Middle East and Africa Benign Prostatic Hyperplasia Treatment Revenue (USD Million) and Growth Rate (2016-2026)

Figure 21. Benign Prostatic Hyperplasia Treatment Market Drivers

Figure 22. Benign Prostatic Hyperplasia Treatment Market Restraints

Figure 23. Benign Prostatic Hyperplasia Treatment Market Trends

Figure 24. Abbott Recent Developments and Future Plans

Figure 25. Allergan plc Recent Developments and Future Plans

Figure 26. Astellas Pharma Recent Developments and Future Plans

Figure 27. Asahi Kasei Corporation Recent Developments and Future Plans

Figure 28. Boehringer Ingelheim GmbH Recent Developments and Future Plans

Figure 29. GlaxoSmithKline Recent Developments and Future Plans

Figure 30. Pfizer Recent Developments and Future Plans

Figure 31. Sanofi Recent Developments and Future Plans

Figure 32. Teva Pharmaceutical Industries Recent Developments and Future Plans

Figure 33. Merck Recent Developments and Future Plans

Figure 34. Boston Scientific Corporation Recent Developments and Future Plans

Figure 35. Teleflex Incorporated Recent Developments and Future Plans

Figure 36. Endo International Recent Developments and Future Plans

Figure 37. Urologix Recent Developments and Future Plans

Figure 38. LISA Laser Recent Developments and Future Plans

Figure 39. Olympus Recent Developments and Future Plans

Figure 40. Global Benign Prostatic Hyperplasia Treatment Revenue Share by Players in 2020

Figure 41. Benign Prostatic Hyperplasia Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

Figure 42. Global Top 3 Players Benign Prostatic Hyperplasia Treatment Revenue Market Share in 2020

Figure 43. Global Top 10 Players Benign Prostatic Hyperplasia Treatment Revenue Market Share in 2020

Figure 44. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)

Figure 45. Global Benign Prostatic Hyperplasia Treatment Revenue Share by Type in 2020

Figure 46. Global Benign Prostatic Hyperplasia Treatment Market Share Forecast by Type (2021-2026)

Figure 47. Global Benign Prostatic Hyperplasia Treatment Revenue Share by Application in 2020

Figure 48. Global Benign Prostatic Hyperplasia Treatment Market Share Forecast by Application (2021-2026)

Figure 49. North America Benign Prostatic Hyperplasia Treatment Sales Market Share by Type (2016-2026)

Figure 50. North America Benign Prostatic Hyperplasia Treatment Sales Market Share by Application (2016-2026)

Figure 51. North America Benign Prostatic Hyperplasia Treatment Revenue Market Share by Country (2016-2026)

Figure 52. United States Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 53. Canada Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 54. Mexico Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 55. Europe Benign Prostatic Hyperplasia Treatment Sales Market Share by Type (2016-2026)

Figure 56. Europe Benign Prostatic Hyperplasia Treatment Sales Market Share by Application (2016-2026)

Figure 57. Europe Benign Prostatic Hyperplasia Treatment Revenue Market Share by Country (2016-2026)

Figure 58. Germany Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 59. France Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 60. United Kingdom Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 61. Russia Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 62. Italy Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 63. Asia-Pacific Benign Prostatic Hyperplasia Treatment Sales Market Share by Type (2016-2026)

Figure 64. Asia-Pacific Benign Prostatic Hyperplasia Treatment Sales Market Share by Application (2016-2026)

Figure 65. Asia-Pacific Benign Prostatic Hyperplasia Treatment Revenue Market Share by Region (2016-2026)

Figure 66. China Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 67. Japan Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 68. South Korea Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 69. India Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 70. Southeast Asia Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 71. Australia Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 72. South America Benign Prostatic Hyperplasia Treatment Sales Market Share by Type (2016-2026)

Figure 73. South America Benign Prostatic Hyperplasia Treatment Sales Market Share by Application (2016-2026)

Figure 74. South America Benign Prostatic Hyperplasia Treatment Revenue Market Share by Country (2016-2026)

Figure 75. Brazil Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 76. Argentina Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 77. Middle East and Africa Benign Prostatic Hyperplasia Treatment Sales Market Share by Type (2016-2026)

Figure 78. Middle East and Africa Benign Prostatic Hyperplasia Treatment Sales Market Share by Application (2016-2026)

Figure 79. Middle East and Africa Benign Prostatic Hyperplasia Treatment Revenue Market Share by Country (2016-2026)

Figure 80. Turkey Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 81. Saudi Arabia Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 82. UAE Benign Prostatic Hyperplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)

Figure 83. Methodology

Figure 84. Research Process and Data Source